Needham & Company LLC restated their buy rating on shares of Generation Bio (NASDAQ:GBIO – Free Report) in a report published on Friday morning,Benzinga reports. The brokerage currently has a $8.00 price target on the stock.
Generation Bio Stock Down 6.3 %
Shares of Generation Bio stock opened at $0.48 on Friday. Generation Bio has a fifty-two week low of $0.47 and a fifty-two week high of $4.65. The firm has a market cap of $32.06 million, a PE ratio of -0.22 and a beta of 2.72. The business’s fifty day moving average is $0.74 and its two-hundred day moving average is $1.51.
Generation Bio (NASDAQ:GBIO – Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The business had revenue of $4.19 million for the quarter, compared to analysts’ expectations of $2.92 million. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. Equities research analysts anticipate that Generation Bio will post -1.75 EPS for the current year.
Insider Transactions at Generation Bio
Institutional Trading of Generation Bio
Several large investors have recently added to or reduced their stakes in the stock. Aegis Wealth Management LLC acquired a new stake in Generation Bio in the 4th quarter valued at $94,000. Jefferies Financial Group Inc. acquired a new stake in Generation Bio in the 4th quarter valued at $2,398,000. Squarepoint Ops LLC acquired a new stake in Generation Bio in the 4th quarter valued at $70,000. Millennium Management LLC acquired a new stake in Generation Bio in the 4th quarter valued at $97,000. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Generation Bio by 13.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 311,535 shares of the company’s stock valued at $330,000 after purchasing an additional 38,090 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.
Generation Bio Company Profile
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
See Also
- Five stocks we like better than Generation Bio
- High Dividend REITs: Are They an Ideal Way to Diversify?
- How to Build the Ultimate Everything ETF Portfolio
- How to Profit From Growth Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Are Treasury Bonds?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.